PF-04191834 Single Dose Bronchodilatory Study In Asthma.
NCT ID: NCT00723021
Last Updated: 2013-02-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
15 participants
INTERVENTIONAL
2008-07-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
NCT01197794
A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects
NCT00830427
Study in Mild Asthmatic Patients
NCT00748306
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma
NCT02219048
A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge
NCT01299467
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PF-04191834 30mg
PF-04191834
30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
PF-04191834 100mg
PF-04191834
100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
PF-04191834 2000mg
PF-04191834
2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
zileuton
zileuton
1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
placebo
Placebo
2 x placebo tablets + placebo oral dispersion, single dose.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-04191834
30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
PF-04191834
100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
PF-04191834
2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
zileuton
1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
Placebo
2 x placebo tablets + placebo oral dispersion, single dose.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Reduced lung function
* Reversible airway obstruction
Exclusion Criteria
* Liver function tests greater than upper limit of normal (ULN)
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
North Dartmouth, Massachusetts, United States
Pfizer Investigational Site
Kalamazoo, Michigan, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B0041002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.